脑部放疗，上午比下午敏感许多！
2 q- \8 M* O4 Q
9 ` ]& c; a1 X9 o8 ?6 p. B1 z( {" a% ~8 \
Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.8 m0 w/ {. a- H/ M# F4 N
Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?3 h! r$ q3 ~$ z
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.# u$ A4 \( c" I" o" G& \$ K3 t/ e) H- @
SourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.1 V9 l) Z$ C( u* u, D
* a7 V0 }& ~5 r1 Z* A. `
Abstract: I @8 X: e4 \! u- w0 f/ f
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.% y3 G% z# U; K
3 c% \% W$ i2 O' O
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic., q( ?1 D+ q( n8 s! Y ?
& f. t9 Z& X z7 M; b0 @* v$ N
RESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).
# l2 i! r- `" M- h& @' Y
5 Y! }7 J! ^, ]0 Y1 H* c# i' cCONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.
+ U' g) I0 P: Z) N! A) D( J; N! C7 [* q3 C' o; f
|
妈妈晚期确诊治疗18个月后的疑惑和不
我的妈妈于2023年12月份确诊肺癌，术中发现胸膜转移，术后基因检测后有EGFR 21
求助 K药和替雷利珠如何选择
父亲9月刚查出非小细胞低分化癌伴随左肾上腺和第10胸椎转移PDL1高表达(TPS=90%) SMARC
生病1年后复查脑MR情况
自生病1年以来，主冶医生也没有开过脑部MR的检查，既然主冶没开就自已做了一个。通过d
肺鳞癌晚期各病灶大幅缩小，骨转不断
62岁的父亲几个月前查出肺鳞癌晚期全身多处转移，目前K药单免中，主病灶和转移灶都在
肺癌靶向治疗耐药的“解药”来了！缓
作者：seacat
SYS6010是石药集团旗下新诺威巨石生物研发的靶向EGFR的ADC。4月底举行的
2 J3 V- _) F; [4 Y |% _) x
显身卡
